Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic-Reference-Cited by-同舟云学术

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic

Published:2021-03-05 Issue:2 Volume:11 Page:543-553
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Kojanova Martina, ,Cetkovska Petra,Strosova Daniela,Fialova Jorga,Arenberger Petr,Dolezal Tomas,Gkalpakiotis Spyridon^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s13555-021-00499-8.pdf

Reference16 articles.

1. Boehncke W-H, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983–94.

2. Menter A. Psoriasis and psoriatic arthritis treatment. Am J Manag Care. 2016;22(8 Suppl):s225-237.

3. Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatol Basel Switz. 2018;234(1–2):1–12.

4. Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450–8.

5. Amin M, Lee EB, Bhutani T, Wu JJ. Review of European registries for psoriasis. J Dermatol Treat. 2019;30(3):227–36.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durability and long-term outcomes of biologic therapies in psoriasis;Expert Review of Clinical Immunology;2023-08-25

2. Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study;Dermatology and Therapy;2023-05-19

3. Long lasting response to anti‐tumor necrosis factor α agents in psoriasis: A real life experience;Dermatologic Therapy;2022-11

4. Factors Associated with Multi-Biologic Use in Psoriasis Patients at an Academic Medical Center and Review of Biologic Survival;Journal of Psoriasis and Psoriatic Arthritis;2022-10-08

5. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry;Journal of Dermatological Treatment;2022-05-29